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ABSTRACT (n = 232) 
Objective:  Update the 2009 Group for Research and Assessment of Psoriasis and 
Psoriatic Arthritis (GRAPPA) treatment recommendations for the spectrum of 
manifestations affecting patients with psoriatic arthritis (PsA).   
Methods:  GRAPPA rheumatologists, dermatologists, and PsA patients drafted 
overarching principles for the management of PsA patients based on consensus at 
face-to-face meetings and via online surveys.  We published literature reviews 
regarding treatment for the key domains of PsA (arthritis, spondylitis, enthesitis, 
dactylitis, skin, and nail disease), and convened a new group to identify pertinent 
comorbidities and their effect on treatment.  Finally, we drafted treatment 
recommendations for each of the clinical manifestations and assessed the level of 
agreement for the overarching principles and treatment recommendations among 
GRAPPA members, with an online questionnaire.  
Results:  Six overarching principles had at least 80% agreement among both health 
care professionals (HCPs; n=135) and patient research partners (PRPs; n=10).  We 
developed treatment recommendations and a schema incorporating these principles for 
arthritis, spondylitis, enthesitis, dactylitis, skin, and nail disease, and comorbidities in the 
setting of PsA, using the GRADE process.  Over 80% agreement was reached for 
approval of the individual recommendations and the overall schema. 
Conclusion:  Herein, we present overarching principles and updated treatment 
recommendations for the key manifestations of PsA, including related comorbidities, 
based on a literature review and consensus of GRAPPA members (rheumatologists, 
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dermatologists, other HCPs, and PRPs).  Further updates are anticipated as the 
therapeutic landscape in PsA evolves. 
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 Psoriatic arthritis (PsA), a disease characterized by inflammatory arthritis, 
enthesitis, dactylitis, and spondylitis in patients with psoriasis,(1, 2) is remarkably 
diverse in presentation and course.  To assist the clinician in the management of PsA, 
the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), 
a global association of over 500 rheumatologists, dermatologists, and patient research 
partners (PRPs) previously published treatment recommendations in 2009(3) based on 
a systematic evidence review published in 2006.(4-11)  To be clinically relevant, such 
recommendations must be dynamic, requiring re-evaluation and appropriate 
modification over time.  In PsA, significant recent developments in pathophysiology and 
disease assessment, particularly the important contribution of comorbidities coupled 
with major therapeutic advances, necessitated an update of the GRAPPA 
recommendations. 
 GRAPPA investigators and PRPs formed groups focused on the clinical domains 
of PsA:  peripheral arthritis, axial disease, enthesitis, dactylitis, skin, and nail disease, 
with a new group focused on comorbidities.  In addition, a representative from each 
group also focused on treatment safety.  Each group then conducted a systematic 
literature review of the PsA treatment literature,(12) and excerpted and published the 
evidence base for treatment effect for each of the domains.(13-19)  We applied the 
GRADE approach to formulate these recommendations,(20) which included 
determination of the strength of recommendation of each therapy (strong, conditional), 
based on the quality and breadth of evidence that the treatment can achieve desirable 
effects (e.g., reduction of morbidity and mortality, improvement in quality of life, 
reduction in burden of treatment and resource utilization), contextualized to individual 
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patient and social considerations.(20)  We created a series of PICO questions (see 
supplementary online data) to address crucial practical questions faced by clinicians 
when making specific treatment choices.  The final treatment schema was critically 
reviewed and edited via in-person discussion and online survey.  It is important to note 
that the purpose of these recommendations is to provide optimal care for PsA patients 
regardless of economic or political considerations. 
 
OBJECTIVE 
 We developed these GRAPPA recommendations to provide up-to-date 
systematic and evidence-based guidance for the treatment and management of adult 
patients with PsA.  These recommendations are not specifically relevant for patients 
with juvenile idiopathic arthritis or psoriasis only.  As noted, updated recommendations 
were required due to significant advances in the field since the 2009 GRAPPA 
treatment recommendations.  For example, several new compounds were approved 
since the 2006 literature review and further evidence has accumulated on existing 
therapies.  The target audience for these GRAPPA recommendations is anyone 
involved in the treatment of PsA patients.   
 
METHODS 
 To help frame these updated GRAPPA recommendations, we developed new 
overarching principles for the treatment of PsA.  Initially drafted by a small working 
group, these overarching principles were refined through several rounds of 
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dissemination to members, followed by live review and discussion at GRAPPA 
meetings.  Subsequently, we posted the principles online for further comment and to 
obtain agreement among GRAPPA membership. GRAPPA members updated the 
reviews that were previously published,(13-19) reviewing subsequent literature within 
six sub-groups addressing peripheral arthritis, axial disease, enthesitis, dactylitis, 
psoriasis, and nail disease in the setting of PsA.  A central literature search was 
performed in collaboration with University of Leeds Library as detailed previously(12) in 
2013 with relevant papers given to the groups.  We convened an additional group to 
assess relevant comorbidities and they performed an independent literature review. The 
psoriasis and nail group were led by dermatologists and rheumatologists led the 
musculoskeletal manifestation groups. The review of the evidence to create treatment 
recommendations was performed using the GRADE system.(20)  As the basis for the 
recommendations, each group developed appropriate PICO (population, intervention, 
comparator, outcomes) questions,(20) and then gathered relevant evidence to support 
the recommendation for individual drugs, classes of drugs, and treatment approaches 
within the six disease domains of PsA as well as the comorbidities group.  
Recommendations could be for or against a treatment, and could be strong or 
conditional, based upon the best scientific evidence and relevant clinical context per the 
GRADE system.  Evidence was combined from the central 2013 literature review and 
additional literature reviews performed within the groups. To ensure that the 
recommendations were not outdated rapidly, each group completed a further literature 
update and review of abstracts through the American College of Rheumatology (ACR) 
Annual Meeting in November 2014, and the American Academy of Dermatology 
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meeting in March 2015.  The comorbidities group performed a individual literature 
searches for each comorbidity that was identified as a key issue in PsA at earlier 
GRAPPA meetings(19, 21). 
The entire group decided that recommendations based on high quality studies 
published only as abstracts should be considered conditional only and clearly 
demarcated by lighter text in the treatment schema.  The group acknowledged that 
these abstracts would likely be published as peer reviewed manuscripts in the near 
future and that the data would impact treatment decisions.  The recommendations for 
specific agents within each domain were summarized in a treatment table and reviewed 
via an online survey by the GRAPPA membership (with the supporting PICO questions) 
to allow feedback, followed by a vote to assess level of agreement.   
 Using these evidence-based data, each group summarized their treatment 
recommendations in a flowchart to guide therapy.  Input from each group was combined 
into a single schema, which was sent to the full GRAPPA membership (including the 
group/committee members) via an online survey for feedback and agreement. 
Throughout the development of these recommendations, GRAPPA members 
who are pharmaceutical industry representatives have been excluded from participation 
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 Six overarching principles for the care of patients with PsA were finalized after 
extensive feedback.  Agreement was ≥80% among GRAPPA members (135 health care 
providers and 10 patient research partners) for all of these principles from both 
physicians and PRPs (Table 1).  The majority of disagreements related to minor 
wording changes, which were incorporated where possible following this survey, 
although a repeat survey was not performed. 
 
GRADE Recommendations for Therapies 
 Each group produced a number of PICO questions addressing the efficacy and 
safety of the different therapies, developing a GRADE based strong/conditional 
recommendation for each therapy within their domain (Supplementary Material 1).  
These are summarized in Table 2 showing which therapies are strongly or conditionally 
recommended within the domains.  A survey of GRAPPA members showed an 87.2% 
support (n=176) for this summary table, including 83.3% of PRPs (n=6). 
 
GRADE Recommendations for Comorbidities  
 The comorbidities group also produced a number of PICO questions addressing 
recommendations for the investigation and management of relevant comorbidities 
(Supplementary Material 2).  Evidence for these issues is limited and the majority of 
these recommendations rely on expert opinion. 
 Identifying comorbidities is critical in the optimal management and treatment of 
PsA patients.  Common comorbidities include cardiovascular disease (CVD), diabetes, 
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obesity, metabolic syndrome, osteoporosis, non-alcoholic fatty liver disease (NAFLD), 
and depression; in addition, some comorbidities might be considered extra-articular 
manifestations of disease, such as inflammatory bowel disease (IBD) and ophthalmic 
disease (e.g., uveitis).  Given the increased prevalence and incidence of CVD and 
diabetes among PsA patients, appropriate screening is recommended.  All PsA patients 
should be encouraged to achieve and maintain a healthy body weight.  This is of 
specific relevance to PsA, as patients with normal body weight using tumor necrosis 
factor inhibitors (TNFi) appear to have a higher likelihood of reducing their disease 
activity than do overweight PsA patients.(22-24)  Given the association of ophthalmic 
disease with the spondyloarthritidies and an increased risk for IBD among PsA patients, 
consideration of screening for eye disease and gastrointestinal disease is 
recommended as a part of the review of systems.  Screening should also be considered 
for anxiety or depression and for skin cancer in patients with both a history of ultraviolet 
(UV) phototherapy and TNFi use.  Comorbidities such as NAFLD, osteoporosis, and 
malignancy also may influence management but have been less commonly associated 
with PsA. 
 Recommendations for treatment of comorbidities in PsA are summarized in 
Table 3. Screening for Human Immunodeficiency Virus, Hepatitis B Virus, Hepatitis C 
Virus, and tuberculosis should be strongly considered, in accordance with local 
guidelines and standards of medical practice, before initiation of therapies that may 
potentially alter normal immune responses.  Depression and anxiety have a high 
prevalence in PsA patients; of note, a warning to weigh the risks and benefits of 
treatment among patients with a history of depression and/or suicidal thoughts/behavior 
Page 13 of 112
John Wiley & Sons
Arthritis & Rheumatology
For Peer Review
05 July 2015 Page 13 of 43 
has been added to the package insert materials in the USA for new drugs for PsA and 
psoriasis.  Although screening and management of comorbidities may be no different 
than for the general population, it is nevertheless important to actively identify them in 
order to optimize the care of patients with PsA.   
 
Treatment Schema 
 Each disease domain group designed a flowchart for treatment of their domain 
using the GRADE recommendations for therapies previously developed.  These were 
combined into a single schema for the management of PsA.  Following feedback from 
the membership, the distinction between mild, moderate and severe disease, which was 
included in the previous GRAPPA grid, was removed because the cut-offs are not 
evidence-based or applicable to all patients.  Figure 1 outlines potential therapeutic 
routes described as standard or expedited to allow therapy to be tailored to the 
individual patient.  Individual treatment decisions with each patient may be dependent 
on disease activity, prognostic factors, comorbidities, and local access to therapies.  
Central to the schema is the concept that optimal care is an iterative process.  As 
alluded to in the overarching principles, we strongly recommend repeated evaluation 
over time and alteration in therapy as appropriate. The schema was circulated to the full 
GRAPPA membership and 87.9% approved (n=176), including all six PRPs.  For clarity, 
it was decided to use the historical term “DMARD” for conventional systemic drugs such 
as methotrexate and sulfasalazine, as this is commonly used nomenclature.  It should 
be noted that this term is not meant to imply that such therapies have “disease 
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modifying” impact on radiographic damage in PsA.  “Biologics” was used to describe the 
group of biological therapies targeting TNF, IL12/23, IL17 and others. 
 This schema is designed to assist in decision making for individual patients, with 
assessment of which disease domains are involved and their relevant comorbidities.  
Many patients have multiple manifestations of their disease and the choice of treatment 
should be considered carefully to ensure that it addresses as many of those as 
possible.  Within this consideration, it is likely that selection of therapy will be driven by 
the most severe element of a person’s disease.  The possibilities for how the schema 
and supporting materials might actually be used are illustrated through case examples 
in Table 4.  
 Further notes regarding this schema are provided below. 
 Peripheral arthritis:  Nonsteroidal anti-inflammatory drugs (NSAIDs) are 
conditionally recommended for use in peripheral arthritis to improve symptoms of the 
disease with caution due to their potential adverse effects.  Corticosteroids are 
conditionally recommended for peripheral arthritis either given systemically or intra-
articularly with the smallest doses required (usually less than 7.5 mg/day) and for short 
periods to minimize adverse effectsincluding psoriasis flare, after CS withdrawal.  In 
disease-modifying antirheumatic drug (DMARD)-naïve patients, both DMARDs 
(methotrexate, leflunomide, sulfasalazine; cyclosporine is not recommended due to 
small evidence of its efficacy and its toxicity profile) and TNFi are strongly 
recommended for treatment.  In many instances, DMARDs may be used first, but 
consideration should be given to early escalation of therapy particularly in patients with 
poor prognostic factors (e.g., raised inflammatory markers, high active joint counts).  
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Despite the lack of evidence from randomized controlled trials (RCTs), DMARDs are 
recommended based on data from observational studies, their low costs and universal 
access, and the lack of evidence that a short time delay in the introduction of more 
effective therapies would impact long-term function and quality of life.  Data concerning 
the PDE4i apremilast in DMARD-naïve patients are only currently available in abstract 
form, hence this is conditionally recommended.  For patients failing DMARDs, PDE4i or 
biologics (including TNFi, interleukin [IL]12/23 inhibitor) are strongly recommended; at 
present a conditional recommendation is given for IL17i as the phase III data are only 
available in abstract form.  It must be noted that there are no data available assessing 
the impact of PDE4i on radiographic damage in contrast to the TNFi, IL12/23i and IL17i.  
One phase 2 RCT showed modest effects with abatacept on joint symptoms in PsA 
Mease(25). Phase 3 trials are being conducted but results are not as yet known Since 
the manufacturer has not submitted it for regulatory approval anywhere in the world, it 
was not included in the current recommendations. We recognize that off-label use may 
occur based on the positive phase 2 study.  There is no definitive evidence to date 
assessing the benefit of concomitant DMARDs with biologic therapies.  In the TNFi 
RCTs, similar efficacy results were commonly seen with or without methotrexate.  
However, registry data suggest a longer persistence of effect of the monoclonal 
antibodies with concomitant DMARDs, particularly with infliximab.  In the case of 
biologic failure either due to adverse events or inefficacy, a large volume of 
observational data are now available supporting the conditional recommendation of 
“switching” to an alternative biologic either within a drug class or to a drug with a 
different mode of action.  Many more recent RCTs include patients who have previously 
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failed one or more biologic therapy(26-28).  There is limited data available on combining 
therapies and treatment strategy in PsA as outlined in the peripheral arthritis evidence 
review (13). MTX in combination with biologic agents, either non-TNFi or anti-TNFi, may 
have a role, but most studies suggest that the combination does not improve clinical 
symptoms beyond those attained by biologic monotherapy (13). Some registry studies 
have shown improved survival, mainly for infliximab (13). 
 Axial disease:  The treatment recommendations for axial disease are derived 
from diagnostic criteria, screening, monitoring and response to therapy in ankylosing 
spondylitis (AS) since these data are not available for axial PsA.  For patients with axial 
symptoms who have not responded to NSAIDs, physiotherapy, and sacroiliac injections 
(when appropriate), initiation of TNFi is recommended; DMARDs are not effective for 
treatment of this domain.  No evidence is available for efficacy of sulfasalazine in axial 
disease within AS or PsA.(29)  Clinical trial data showing efficacy for secukinumab 
(phase III trial)(30) and ustekinumab (an open-label proof-of-concept trial with 20 
patients)(31) have been published in AS, but these agents are currently not approved 
for AS or axial PsA.  Formal published data on switching agents for axial disease are 
not available. 
 Enthesitis:  NSAIDs are the first line agents in treatment of enthesitis based on 
expert opinion, however data from RCTs are lacking (32).  Physiotherapy is also often 
prescribed although formal studies of efficacy are lacking.  In one study with defined 
enthesitis endpoints and placebo controls, sulfasalazine was not effective (33), and no 
published data support efficacy of other DMARDs in placebo-controlled studies (15, 32). 
There is high quality evidence for the effectiveness of, TNFi and ustekinumab (15).  
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Data on the efficacy of PDE4i (34) and secukinumab (35) for enthesitis in PsA are 
published as abstracts only.  Formal data on switching are not available.  
 Dactylitis:  In contrast to enthesitis, DMARDs were recommended as a first step 
in dactylitis based on limited studies for this indication.  Corticosteroid injections should 
also be considered, although no formal studies of this intervention have been published.  
There are efficacy data for biologics (TNFi or ustekinumab), but data on switching are 
not available.  Published abstracts show efficacy for both PDE4i(34) and 
secukinumab(35) for dactylitis, but again, data on switching agents are not available.  
 Skin disease: Topical agents are generally the first level of treatment for 
psoriasis, particularly milder disease, followed by phototherapy and DMARDs. 
Treatment may be initiated with topical therapies in combination with phototherapy or 
DMARDs in patients with wide-spread disease.  For patients who do not respond to 
these therapies, biologics are recommended.  Biologics may be first-line therapy, with or 
without topical therapies and DMARDs, in certain patients.  Switching from one DMARD 
to another, from a DMARD to a biologic, or from one biologic to another can be done.  
 Nail disease:  Recommendations for the treatment of nail disease in PsA rely on 
data from studies in skin psoriasis; there are relatively few studies, some of which had 
methodologic issues affecting their interpretation.(11, 18)  The best data were produced 
in studies of biologics, particularly the TNF inhibitors, and these agents would certainly 
be recommended for PsA patients with moderate to severe nail involvement.  High 
quality data are also published on alternative biologics, including ustekinumab and IL-17 
inhibitors, and these agents could be considered alternative biologic therapies to TNFi.  
Efficacy on nail disease in psoriasis RCTs has been confirmed for PDE4i in multiple 
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abstracts but no published paper was available at this time.  Despite the paucity of data, 
topical agents, corticosteroid injections, or non-biologic DMARDs could be considered, 
especially for patients with milder involvement or contraindications to other therapies.  
  
Research Agenda 
 Tremendous advances have transpired in the therapeutic approach to PsA.  
Indeed, such progress, along with a desire to codify the data into recommendations that 
could assist clinicians caring for PsA patients, were a major impetus to the formation of 
GRAPPA.  Substantial developments since the initial GRAPPA recommendations 
necessitated their update.  With gr ater success, the goals of treatment have become 
increasingly elevated, as reflected in the overarching principles presented herein.  In 
order to better achieve those lofty goals, we eagerly anticipate research into and data 
from a number of key areas.  
 1.  Outcome measures.  It is hoped that development, refinement, and 
ultimately, implementation of PsA-specific outcome measurements will facilitate 
evaluation and treatment of individual patients in the clinic as well as further enhancing 
PsA research.  
 2.  Biomarkers.  Despite tremendous advances in therapies and treatment 
strategies, there is still an unmet need identifying the optimal therapeutic approach for 
individual PsA patients.  Also, the heterogeneity of PsA remains largely unexplained.  
Although we know that 30% of psoriasis patients will develop PsA, often after several 
years, we cannot reliably identify such patients.  
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 3.  Better Identification and treatment of patients.  Several reports emphasize 
potentially poor outcome for patients with PsA.(36, 37)  Moreover, recent evidence 
demonstrated that a delay in diagnosis and delayed access to appropriate treatment are 
key predictors of poor outcome, in terms of response to therapy,(38) joint damage,(39) 
and functional ability.(39, 40)   Unfortunately, data from market surveys and other 
sources show that many PsA patients may not be receiving appropriate therapy.  For 
example, in a telephone survey of more than 700 PsA patients, the majority were on 
topical therapy only (31%) or no treatment at all (28%), and 16% reported not seeing 
any healthcare provider in the past year for their PsA.(41)  
 4.  Treatment strategies.  Novel treatment strategies are being assessed in 
PsA.  For example, treat-to-target, a concept well established in rheumatoid 
arthritis,(42) is now being explored in PsA.  Understanding the overall long-term utility of 
this approach in PsA will be crucial to defining the best treatment approach.  Another 
concept that has been more extensively studied in RA is whether therapies can be 
tapered or even discontinued by patients reaching their therapeutic goals.  It remains to 
be determined whether this will be possible, and for which patients, in PsA.  
 
DISCUSSION 
 Herein, the members of GRAPPA present updated evidence-based treatment 
recommendations for patients with PsA.  Optimal management of PsA using a 
multidisciplinary and multispecialty approach is required but remains a major challenge.  
The heterogeneity of the disease requires assessment of multiple PsA domains to 
identify appropriate treatments for each individual.  Assessment of comorbidities is also 
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key when planning therapy and can either lead to an escalation in therapy for related 
diseases, such as inflammatory bowel disease or uveitis, or requires a dose alteration 
or restriction of therapies in the presence of liver disease or increased risk of infection. 
 These recommendations are evidence-based wherever possible and result from 
literature searches updated to October 2014 and also include data from the American 
Academy of Dermatology Annual Meeting in March 2015.  We performed our evidence 
review using GRADE, the format recommended by a number of international bodies 
including the World Health Organization.  The recommendations had strong patient 
involvement (PRPs were represented in each group) and their feedback was 
incorporated in the overall schema and tables presented here.  First, international 
experts and patients reached consensus in the individual groups over multiple 
iterations, both for the individual domains and for the overall project.  Subsequently, we 
obtained consensus on the formal recommendations from the entire GRAPPA 
membership and PRPs and we recorded the extent of agreement for recommendations 
in each domain, including comorbidities.  To maximise impartiality, GRAPPA members 
from the pharmaceutical industry were excluded from discussions and voting on the 
recommendations.  To maximise feedback, all non-pharmaceutical members were 
invited to respond although their individual conflicts of interest are not available. 
 While other relevant information may be available, it is worth noting that these 
recommendations were not developed specifically for patients with psoriasis alone, nor 
for children with PsA.  They are designed to be relevant across international boundaries 
although it must be recognized that access to some therapies is not universal.  We also 
recognize that limited available evidence exists particularly for some relevant clinical 
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questions.  For example, high quality evidence to support the standard treatment 
approaches in PsA are not published in every domain, and we lack evidence-based 
studies on the potential additive or even synergistic benefit of combinations of agents 
(e.g., methotrexate and TNFi).  Most importantly, evidence is not available at this time to 
support optimal treatment pathways, such as the treatment of early PsA, the overall 
utility of treat-to-target in PsA, and whether it is better to switch to treatments with a 
different mechanism of action in patients who have insufficient clinical responses to one 
agent in a class.  
 The members of GRAPPA agreed to include the latest recent literature including 
high quality abstracts from recent meetings; thus, agents not yet licensed or approved 
for PsA were included.  These agents are clearly demarcated in the schema using grey 
font and details of these therapies are provided in the text.  In these cases, drugs are 
only given conditional recommendations, but have been included to provide up-to-date 
information. 
 These recommendations represent the literature at present but the 
recommendations may change with new evidence in future.  Just as these 
recommendations are updates of those published in 2009, they will require further 
updating to ensure that the recommendations reflect current evidence and practice.
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1 The ultimate goals of therapy for all patients with 
psoriatic arthritis (PsA) are: a) To achieve the lowest 
possible level of disease activity in all domains of 
disease; as definitions of remission and low or minimal 
disease activity become accepted, these will be 
included in the goal.  b) To optimize functional status, 
improve quality of life and wellbeing, and prevent 
structural damage to the greatest extent possible. c) To 
avoid or minimize complications, both from untreated 
active disease and from therapy. 
92.6% 80% 
2 Assessment of patients with PsA requires consideration 
of all major disease domains, including peripheral 
arthritis, axial disease, enthesitis, dactylitis, psoriasis, 
and nail disease.  The impact of disease on pain, 
function, quality of life, and structural damage should be 
examined.  In addition, activity in other potential related 
83.7% 80% 
Page 29 of 112
John Wiley & Sons
Arthritis & Rheumatology
For Peer Review








conditions should be considered, including 
cardiovascular disease, uveitis, and inflammatory bowel 
disease.  Multidisciplinary and multispecialty 
assessment and management will be most beneficial for 
individual patients. 
3 Clinical assessment ideally includes patient-reported 
measures with a comprehensive history and physical 
examination, often supplemented by laboratory tests 
and imaging techniques (e.g., x-ray, ultrasound, MRI).  
The most widely accepted metrics that have been 
validated for PsA should be utilized whenever possible. 
88.9% 80% 
4 A comprehensive assessment of relevant comorbidities 
(including but not restricted to obesity, metabolic 
syndrome, gout, diabetes, cardiovascular disease, liver 
disease, depression and anxiety) should be undertaken 
and documented.   
85.2% 100% 
5 Therapeutic decisions need to be individualized, and 
are made jointly by the patient and their doctor.  
89.6% 80% 
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Treatment should reflect patient preferences, with the 
patients provided with the best information and relevant 
options provided to them.  Treatment choices may be 
affected by various factors, including disease activity, 
structural damage, comorbid conditions and previous 
therapies. 
6 Ideally, patients should be reviewed promptly, offered 
regular evaluation by appropriate specialists, and have 
treatment adjusted as needed in order to achieve the 
goals of therapy. Early diagnosis and treatment is likely 
to be of benefit. 
89.6% 80% 
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as lack of 
evidence 
PDE4i 
Italicized text identifies conditional recommendations for drugs without current regulatory 
approvals or where recommendations are based on abstract data only.   
Italicized text in brackets identifies a conditional recommendation based only on abstract data 
from a small open-label proof-of-concept trial.  
ADM = adalimumab, AS = ankylosing spondylitis, CD20i = CD20 inhibitor, CS = corticosteroids, 
CyA = cyclosporin, CZP = certolizumab, DMARDs = disease modifying anti-rheumatic drugs, 
GOL = golimumab, IA = intra-articular, IL6i = interleukin 6 inhibitor, IL17i = interleukin 17 inhibitor, 
IL12/23i = interleukin 12/23 inhibitor, INF = infliximab, LEF = leflunomide, MTX  = methotrexate, 
NSAIDs = nonsteroidal anti-inflammatory drugs, PDE4i = phosphodiesterase 4 inhibitor 
(apremilast), SEC = secukinumab, SIJ = sacroiliac injections, SSZ = sulfasalazine, TNFi = tumor 
necrosis factor inhibitor  
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C ? NI NI NI NI NI NI NI NI NI NI ? NI 
Congestive Heart 
Failure 
C C NI NI NI NI NI ? ? ? ? ? ? NI 
Obesity NI NI NI NI C NI NI NI NI NI NI NI NI NI 
Metabolic Syndrome NI C NI NI C NI NI NI NI NI NI NI NI NI 
Diabetes NI C NI NI C NI NI NI NI NI NI NI NI NI 
Ulcerative Colitis ? NI NI A NI NI OL NI A A NI A NI NI 
Crohn’s Disease ? NI NI A OL NI NI NI A A A NI NI NI 
Uveitis NI P# NI NI NI NI NI ? P P NI NI NI NI 
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Osteoporosis NI C NI NI NI NI NI NI NI NI NI NI NI NI 
Malignancy NI NI NI NI NI NI NI C C C C C ? NI 
Fatty Liver Disease C NI NI C C C NI NI NI NI NI NI NI NI 
Chronic Kidney 
Disease 
C NI NI NI C ? SM NI NI NI NI NI NI NI 
Depression NI NI NI NI NI NI NI NI NI NI NI NI NI ? 
Chronic Hepatitis B * C NI NI NI C C NI SM SM SM SM SM ? NI 




       SM SM SM SM SM ?  
Page 37 of 112
John Wiley & Sons
Arthritis & Rheumatology
For Peer Review














































































































































































































A    = Approved for primary therapy of the comorbid condition 
C    = Reason for caution 
NI = no information available 
OL  =  Off-label use for the therapy of the comorbid condition 
P    =  Preferred therapy 
SM =  Requires special monitoring 
?    =  Data insufficient but concerns have been raised 
*  When treating patients with chronic infections that can affect the liver, consider consultation with 
providers having expertise in the area. 
# Corticosteroids used as preferred therapy for uveitis are given as topical and/or intraocular injections in 
preference to oral steroids 
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Table 4:  Case studies using treatment recommendations 
Case 
1 
43-year-old man, psoriasis for 10 years, psoriatic arthritis for 1 year.  Current 
evaluation: SJ2 TJ3 (PIPs and DIPs); no axial symptoms; 3 tender enthesial 
sites; no dactylitis; psoriasis self-rated 1/10 with BSA 2% (elbows, knees, 
buttocks) and no nail involvement.  Prior therapy has been only NSAIDs, and 
topical steroids, which he remains on at present.  Additional history notable for 
3 episodes of iritis over the past 18 months, treated with steroid eye drops.  
 
Treatment recommendation options: TNF inhibitor, DMARD 
 
Discussion:  With reference to the treatment schema, for the individual domains 
of peripheral arthritis and enthesitis and skin, DMARD treatment, e.g.LEF, MTX, 
could be a viable choice given the relatively modest activity in each domain.  
However, the presence of recurrent iritis (see comorbidity table) along with the 
combination of individual domains, supports escalation of therapy.  Hence, TNF 
inhibitor therapy is a reasonable choice, and should be discussed with the 
patient.  In some areas, clinicians may be obliged to use MTX before access to 
a TNF inhibitor is allowed.  Other newer therapies could be considered (e.g., IL-
12/23 inhibitor, PDE4i [apremilast], IL-17 inhibitors) although clinicians have 
longer experience with older medications.  
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59-year-old woman, psoriasis for 15 years, psoriatic arthritis for 9 months.  
Current evaluation: SJ6, TJ8 (knees, wrist, fingers); no axial symptoms; 
1 tender enthesial site; no dactylitis; psoriasis self-rated 4/10 with BSA 8% 
(trunk, scalp, arms, legs) and nail involvement.  Prior treatment: cyclosporine 
led to hypertension, NSAIDs worsened renal function.  Cannot access UV 
therapy.  Currently on topical steroids.  Additional history notable for poorly 
controlled diabetes, obesity, and recurrent sinusitis with one hospitalization for 
pneumonia in the past year.   
 
Treatment recommendation options: methotrexate, PDE4i, leflunomide, 
biologics 
 
Discussion:  Referring to the treatment schema, moderate to severe activity in 
the peripheral joints and skin seem to be the main drivers of therapy.  However, 
comorbidities (see table) are very important in this case.  Excluding failed 
therapies, these options remain.  MTX is a difficult choice due to obesity and 
diabetes as potential drivers of hepatotoxicity with MTX.  The recurrent 
infections are a concern across most immunomodulatory therapies.  Clearly, 
extended discussion of potential risk/benefit with the patient is required, along 
with close monitoring.  Assessment of existing radiographic damage may also 
inform treatment choice. 
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34 year old woman with psoriasis for 4 years, psoriatic arthritis for 2 years.  
Current evaluation: SJ8 TJ12 (wrist, knee, fingers, toes); no axial symptoms; 
7 tender enthesial sites (knees, feet, pelvic rim); dactylitis of 2 toes (causing 
inability to walk as required for her work); skin self-rated 1/10 with 1% BSA 
(trunk) without nail involvement.  Prior treatments: methotrexate tried, but 
caused liver function abnormalities possibly related to alcohol use.  Current 
treatment with NSAIDs, topical low dose steroids, and assist devices (heel cup 
for foot enthesitis).  Treatment with TNF was recommended but the patient was 
hesitant to do injections or infusions.  After considerations of options, and 
discussion of sulfasalazine, leflunomide, and PDE4i, patient chose sulfasalzine.  
On re-evaluation 4 months later, there was no improvement.  Patient agreed to 
therapy with TNF inhibitor.  After 3 months of therapy, she reported 
improvement across domains of “around 40%” (but was not achieving the 
minimal disease activity criteria) and also noted mild but bothersome injection 
site reactions.  
 
Treatment recommendations (in no order of preference): A different TNF 
inhibitor, IL-12/23 inhibitor, IL-17 inhibitor, leflunomide, and PDE4i. 
 
Discussion:  Referring to the treatment schema, there are several alternatives 
as noted.  Given the significant impact on the patient’s quality of life, treatment 
needs to be highly effective for this patient.  In this case, it can be debated 
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whether the patient is a “TNFi failure,” and also whether switching to alternative 
TNFi or to another biologic with a different mode of action would be preferred.  
BSA = body surface area; DIP = distal interphalangeal joint; DMARD = disease 
modifying anti-rheumatic drug; MTX = methotrexate, NSAID = nonsteroidal anti-
inflammatory drug; PDE4i = phosphodiesterase 4 inhibitor (apremilast); PIP = proximal 
interphalangeal joint; SJ = swollen joint; TJ = tender joint; TNFi = tumor necrosis factor 
inhibitor 
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Figure Legend 
 
Figure 1:  GRAPPA Treatment Schema for Active PsA 
Grey text identifies conditional recommendations for drugs without current regulatory 
approvals or where recommendations are based on abstract data only. 
 
DMARDs = disease modifying anti-rheumatic drugs, IL17i = interleukin 17 inhibitors, 
IL12/23i = interleukin 12/23 inhibitors, LEF = leflunomide, MTX = methotrexate, NSAIDs 
= nonsteroidal anti-inflammatory drugs, PDE4i = phosphodiesterase 4 inhibitor 
(apremilast), SSZ = sulfasalazine, TNFi = tumor necrosis factor inhibitor 
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inhibitor  
 
190x142mm (300 x 300 DPI)  
 
 
Page 45 of 112
John Wiley & Sons
Arthritis & Rheumatology
For Peer Review
GRAPPA Treatment Recs for PsA, Suppl Materials I Page 1 of 19  
GRAPPA Treatment Recommendations: 
PICOs and GRADE Recommendations by Group 
Peripheral Arthritis 
1. In patients with active peripheral PsA what is the impact of non-steroidal anti-
inflammatory drugs (NSAIDs) on symptoms, disease progression and adverse events? 
NSAIDs can be considered to relieve symptoms of peripheral PsA, at a standard or 
lower dose and with careful monitoring for side effects if used in a sustained manner.   




desirable and undesirable 
effects 
Short term desirable effect. No effect on disease 
progression proven. Adverse events are common. 
Quality of evidence Low quality 





2. In patients with active peripheral PsA what is the impact of oral steroids on symptoms, 
disease progression and adverse events? 
Chronic systemic corticosteroids are not recommended in the treatment of psoriatic 
arthritis and are only advisable in discrete circumstances for short-term disease control 
and not for chronic use. 




desirable and undesirable 
effects 
Short term desirable effect. No effect on disease 
progression proven. Potential for significant adverse 
events with long term use.    
Quality of evidence Very low quality 





3. In patients with active peripheral PsA, with or without ongoing DMARD treatment, what 
is the impact of intra-articular steroids on symptoms, disease progression and adverse 
events? 
Intra-articular corticosteroids are recommended for symptom alleviation in the treatment 
of psoriatic mono-, oligo- and polyarthritis. 
Strength of recommendation – conditionally recommended 
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Factor Comment 
Balance between 
desirable and undesirable 
effects 
Short term desirable effect. No effect on disease 
progression proven. Adverse events are rare. 
Quality of evidence Very low quality 





4. In patients with active peripheral PsA what is the impact of conventional disease 
modifying anti-rheumatic drugs (cDMARDs) on symptoms, disease progression and 
adverse events? 
Conventional DMARDs (methotrexate, leflunomide, sulfasalazine) are recommended as 
a first line therapy for symptoms of peripheral PsA  




desirable and undesirable 
effects 
Clear desirable effect. Favorable balance between 
desirable and undesirable effects. No clear harmful 
effect of a short term delay ( 3-6 months) in introducing 
more effective treatments. 
Quality of evidence Moderate quality 





5. In patients with active peripheral PsA who are DMARD-naive what is the impact of TNF 
inhibitors on symptoms, disease progression and adverse events? 
TNF inhibitors should be used to treat symptoms  and disease progression of peripheral 
PsA in people who are DMARD naive 




desirable and undesirable 
effects 
Strongly favors desirable effects on symptoms and 
disease progression. 
Quality of evidence High Quality RCT data for adalimumab, etanercept, 
golimumab, infliximab 
Values and preferences well established  values and preferences 
Costs (resource 
allocation) 
High cost.  
 
6. In patients with active peripheral PsA who are DMARD-naive what is the impact of 
IL12/23 inhibitor on symptoms, disease progression and adverse events? 
IL12/23 inhibitors is not recommended to treat symptoms of peripheral PsA in people 
who are DMARD naive 
Strength of recommendation – conditionally not recommended 
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desirable and undesirable 
effects 
No data in DMARD naïve patients 
Quality of evidence No data available 





7. In patients with active peripheral PsA who are DMARD-naive what is the impact of IL17 
inhibitors on symptoms, disease progression and adverse events?  
IL17 inhibitors should (not) be used to treat symptoms of peripheral PsA in people who 
are DMARD naive 




desirable and undesirable 
effects 
No data in DMARD naïve patients 
Quality of evidence No data available 





8. In patients with active peripheral PsA who are DMARD-naive what is the impact of 
apremilast on symptoms, disease progression and adverse events?  
Apremilast can be considered to treat symptoms of peripheral PsA in people who are 
DMARD naive 




desirable and undesirable 
effects 
Likely effect on symptoms of peripheral PsA, no data on 
disease progression, adverse events are uncommon 
Quality of evidence Low quality (abstract of 1 RCT only) 





9. In patients with active peripheral PsA who have failed conventional DMARDs what is the 
impact of TNF inhibitors on symptoms, disease progression and adverse events? 
TNF inhibitors should be used to treat symptoms and disease progression of peripheral 
PsA in people who have failed conventional DMARDs 
Strength of recommendation – strongly recommended 
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Factor Comment 
Balance between 
desirable and undesirable 
effects 
Strongly favors desirable effects. 
Quality of evidence High Quality 
Values and preferences well established  values and preferences 
Costs (resource 
allocation) 
High cost.  
 
10. In patients with active peripheral PsA who have failed conventional DMARDs what is the 
impact of IL12/23 inhibitors on symptoms, disease progression and adverse events? 
IL12/23 inhibitors should be used to treat symptoms and disease progression of 
peripheral PsA in people who have failed conventional DMARDs 




desirable and undesirable 
effects 
Strongly favors desirable effects. 
Quality of evidence High Quality 
Values and preferences well established  values and preferences 
Costs (resource 
allocation) 
High cost.  
 
11. In patients with active peripheral PsA who have failed conventional DMARDs what is the 
impact of IL17 inhibitors on symptoms, disease progression and adverse events? 
IL17 inhibitors should be used to treat symptoms and disease progression of peripheral 
PsA in people who have failed conventional DMARDs 




desirable and undesirable 
effects 
Strongly favors desirable effects. 
Quality of evidence High Quality studies but phase III studies only in 
abstract form currently 
Values and preferences well established  values and preferences 
Costs (resource 
allocation) 
High cost.  
 
12. In patients with active peripheral PsA who have failed conventional DMARDs what is the 
impact of apremilast on symptoms, disease progression and adverse events? 
Apremilast should be used to treat symptoms of peripheral PsA in people who have 
failed conventional DMARDs 
Strength of recommendation – strongly recommended 
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Factor Comment 
Balance between 
desirable and undesirable 
effects 
Strongly favors desirable effects on symptoms, no data 
on disease progression. 
Quality of evidence High Quality 
Values and preferences well established  values and preferences 
Costs (resource 
allocation) 
High cost.  
 
13. In patients with active peripheral PsA what is the impact of switching to an alternate TNF 
inhibitor or to an alternate targeted biological agent on symptoms, disease progression 
and adverse events in the case of inadequate response or adverse effects with a first 
targeted biological agent? 
Switching TNF inhibitors or to an alternate targeted biological agent for inadequate 
response or adverse effects can be considered to treat symptoms of peripheral PsA in 
people with PsA that are not responding to a previous targeted biological agent. 




desirable and undesirable 
effects 
Effective on symptoms of peripheral PsA, likely effect on 
disease progression (TNFi), adverse events are 
common (TNFi, IL17i, IL12/23i), adverse events 
uncommon with apremilast 
Quality of evidence Low quality, little data 






1. In patients with active PsA-related axial disease what is the impact of non-steroidal anti-
inflammatory drugs (NSAIDs) on symptoms, disease progression and adverse events? 
NSAIDs should be used to treat symptoms of axial disease in people with PsA.   




desirable and undesirable 
effects 
Short term desirable effect, positive effect on disease 
progression, adverse events are common 
Quality of evidence High quality 





2. In patients with active PsA-related axial disease what is the impact of physiotherapy and 
simple analgesia on symptoms, disease progression and adverse events? 
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Physiotherapy and simple analgesia should be used to treat symptoms of axial disease 
in people with PsA 




desirable and undesirable 
effects 
Short term desirable effect, no effect on disease 
progression, adverse events are uncommon 
Quality of evidence High quality 





3. In patients with active PsA-related axial disease what is the impact of conventional 
disease modifying anti-rheumatic drugs (cDMARDs) on symptoms, disease progression 
and adverse events? 
Conventional DMARDs should not be used to treat symptoms of axial disease in people 
with PsA 




desirable and undesirable 
effects 
No effect on symptoms or signs of axial disease or on 
disease progression, adverse events are common 
Quality of evidence High quality 





4. In patients with active PsA-related axial disease that is not responding to NSAIDs, what 
is the impact of TNF inhibitors on symptoms, disease progression and adverse events? 
TNF inhibitors should be used to treat symptoms of axial disease in people with PsA that 
are not responding to NSAIDs 




desirable and undesirable 
effects 
Effective on symptoms and signs of axial disease, 
possible effect on disease progression, adverse events 
are common 
Quality of evidence High quality 





5. In patients with active PsA-related axial disease that is not responding to NSAIDs, what 
is the impact of IL12/23 inhibitor on symptoms, disease progression and adverse 
events? 
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IL12/23 inhibitors can be considered to treat symptoms of axial disease in people with 
PsA that are not responding to NSAIDs 




desirable and undesirable 
effects 
No effect on disease progression, adverse events are 
uncommon 
Quality of evidence Low quality (abstract data only) 





6. In patients with active PsA-related axial disease that is not responding to NSAIDs, what 
is the impact of IL17 inhibitors on symptoms, disease progression and adverse events?  
IL17 inhibitors should be used to treat symptoms of axial disease in people with PsA that 
are not responding to NSAIDs 




desirable and undesirable 
effects 
No effect on disease progression, adverse events are 
uncommon 
Quality of evidence Low quality (abstract data only for phase III) 





7. In patients with active PsA-related axial disease that is not responding to NSAIDs,  what 
is the impact of IL6 inhibitor on symptoms, disease progression and adverse events?  
IL6 inhibitors should not be used to treat symptoms of axial disease in people with PsA 
that are not responding to NSAIDs 




desirable and undesirable 
effects 
No effect on symptoms or signs of axial disease or on 
disease progression, adverse events are common 
Quality of evidence High quality 





8. In patients with active PsA-related axial disease that is not responding to NSAIDs, what 
is the impact of anti-CD20 antibodies (rituximab) on symptoms, disease progression and 
adverse events?  
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Anti-CD20 antibody should not be used to treat symptoms of axial disease in people with 
PsA that are not responding to NSAIDs 




desirable and undesirable 
effects 
No effect on symptoms or signs of axial disease or on 
disease progression, adverse events are common 
Quality of evidence High quality 





9. In patients with active PsA-related axial disease that is not responding to NSAIDs, what 
is the impact of sacroiliac joint injections on symptoms, disease progression and adverse 
events?  
Local injection of corticosteroid to the sacroiliac joints can be considered to treat 
symptoms of axial disease in people with PsA that are not responding to NSAIDs. 




desirable and undesirable 
effects 
Short term desirable effect, no effect on disease 
progression, adverse events are uncommon 
Quality of evidence Low quality 





10. In patients with active PsA-related axial disease that is not responding to NSAIDs, what 
is the impact of bisphosphonates on symptoms, disease progression and adverse 
events?  
Bisphosphonate infusions can be considered to treat symptoms of axial disease in 
people with PsA that are not responding to NSAIDs. 




desirable and undesirable 
effects 
Short term desirable effect, no effect on disease 
progression, adverse events are uncommon 
Quality of evidence Low quality 





11. In patients with active PsA-related axial disease what is the impact of switching to an 
alternate TNF inhibitor or to an alternate targeted biological agent on symptoms, disease 
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progression and adverse events in the case of inadequate response or adverse effects 
with a first targeted biological agent? 
Switching TNF inhibitors or to an alternate targeted biological agent for inadequate 
response or adverse effects can be considered to treat symptoms of axial disease in 
people with PsA that are not responding to a previous targeted biological agent. 




desirable and undesirable 
effects 
Effective on symptoms and signs of axial disease, 
possible effect on disease progression, adverse events 
are common 
Quality of evidence Low quality 






1. In patients with active PsA-related enthesitis what is the impact of non-steroidal anti-
inflammatory drugs (NSAIDs) on symptoms and adverse events? 
NSAIDs can be considered as an initial therapy for enthesitis with careful monitoring for 
side effects   




desirable and undesirable 
effects 
Potential desirable effect, adverse events possible but 
serious adverse ffects are uncommon 
Quality of evidence No RCTs, expert consensus 





2. In patients with active PsA-related enthesitis what is the impact of physical therapy on 
symptoms and adverse events? 
Physical therapy can be considered to improve symptoms and functional defecit 
associated with enthesitis  




desirable and undesirable 
effects 
Potential benefit, no adverse events likely 
Quality of evidence No RCTs, expert consensus 
Values and preferences Generally well tolerated and received 
Costs (resource 
allocation) 
Relatively low cost 
Page 54 of 112
John Wiley & Sons
Arthritis & Rheumatology
For Peer Review
GRAPPA Treatment Recs for PsA, Suppl Materials I Page 10 of 19  
 
3. In patients with active PsA-related enthesitis what is the impact of local corticosteroid 
injections on symptoms and adverse events? 
Local corticosteroid injections can be considered with caution for enthesitis  




desirable and undesirable 
effects 
Potential desirable effect, serious adverse events are 
possible  
Quality of evidence Extrapolated results from meta-analysis of controlled 
trials in tendinopathy, high 





4. In patients with active PsA-related enthesitis what is the impact of conventional disease 
modifying anti-rheumatic drugs (cDMARDs) on symptoms and adverse events? 
cDMARDs are not recommended for the treatment of enthesitis  




desirable and undesirable 
effects 
No demonstrated benefit, adverse events are common  
Quality of evidence One RCT 
Values and preferences Not assessed 
Costs (resource 
allocation) 
Low to moderate cost 
 
5. In patients with active PsA-related enthesitis what is the impact of TNF inhibitors on 
symptoms and adverse events? 
TNF alpha inhibitors as a class are recommended as initial or second line therapy in the 
treatment of refractory of moderate to severe enthesitis  




desirable and undesirable 
effects 
Demonstrated benefit, potential serious adverse events 
Quality of evidence High quality RCTs (golimumab, certolizumab, infliximab) 
Non-placebo controlled (etanercept) 
Not enough evidence for adalimumab 
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6. In patients with active PsA-related enthesitis what is the impact of IL12/23 inhibitors on 
symptoms and adverse events? 
Ustekinumab is recommended as initial or second line therapy in the treatment of 
refractory of moderate to severe enthesitis  




desirable and undesirable 
effects 
Demonstrated benefit, potential serious adverse events 
Quality of evidence High quality RCTs  





7. In patients with active PsA-related enthesitis what is the impact of apremilast on 
symptoms and adverse events? 
Apremilast is recommended as initial or second line therapy in the treatment of refractory 
of moderate to severe enthesitis  




desirable and undesirable 
effects 
Demonstrated benefit, low risk of adverse events 
Quality of evidence High quality RCT 





8. In patients with active PsA-related enthesitis what is th  impact of IL17 inhibitors on 
symptoms and adverse events? 
IL17 inhibitors can be considered as an initial or second line therapy in the treatment of 
refractory of moderate to severe enthesitis  




desirable and undesirable 
effects 
Demonstrated benefit (secukinumab), no benefit 
(brodalumab), potential risk of serious adverse events 
Quality of evidence Low, abstract data only from RCT 
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Dactylitis 
1. In patients with active PsA-related dactylitis what is the impact of local corticosteroid 
injections on symptoms and adverse events? 
Local corticosteroid injections can be considered for symptom improvement in dactylitis  




desirable and undesirable 
effects 
Short term desirable effect. No known effect on disease 
progression. Adverse events of steroid injections are 
minor: very small chance (less than 1/1000) of infection. 
Quality of evidence No RCT, little evidence 
Values and preferences Simple treatment regularly administered in practice. Site 
of injection variable. Options include intra-articular, and 





2. In patients with active PsA-related dactylitis what is the impact of conventional disease 
modifying anti-rheumatic drugs (cDMARDs) on symptoms and adverse events? 
cDMARDs (methotrexate, leflunomide, sulfasalazine) can be considered for the 
treatment of dactylitis  




desirable and undesirable 
effects 
As these treatments are likely to be given for active 
disease elsewhere, favorable balance between 
desirable and undesirable effects 
Quality of evidence Weak evidence from RCT. Stronger evidence from 
observational studies 
Values and preferences If dactylitis only feature the systemic effects of treatment 
must be considered but individualiised decisions 
necessary eg may be more urgent in finger of someone 





3. In patients with active PsA-related dactylitis what is the impact of TNF inhibitors on 
symptoms and adverse events? 
TNF alpha inhibitors (adalimumab, certolizumab, golimumab and infliximab) are 
recommended as initial or second line therapy in the treatment of refractory of moderate 
to severe dactylitis  
Strength of recommendation – strongly recommended 
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Factor Comment 
Balance between 
desirable and undesirable 
effects 
Strongly favors desirable effects. Treatment unlikely to 
be given solely for dactylitis so beneficial effects on 
enthesitis, spondylitis and peripheral arthritis must also 
be taken into consideration 
Quality of evidence Strong evidence in RCTs for adalimumab, certolizumab, 
golimumab, infliximab but dactylitis only ever a 
secondary outcome 
Not enough evidence for etanercept 
Values and preferences Well established  values and preferences in light of 
above as skin improvement and other articular both 





4. In patients with active PsA-related dactylitis what is the impact of IL12/23 inhibitors on 
symptoms and adverse events? 
Ustekinumab can be considered as an initial targeted biological therapy or second line 
therapy in the treatment of refractory of moderate to severe dactylitis  




desirable and undesirable 
effects 
Favors desirable effects but MACE events still under 
examination in prospective cohort studies. 
Quality of evidence High quality CT  
Values and preferences Probably well positioned in values and preferences but 






5. In patients with active PsA-related dactylitis what is the impact of apremilast on 
symptoms and adverse events? 
Apremilast can be considered as a second line therapy in the treatment of refractory of 
moderate to severe dactylitis  




desirable and undesirable 
effects 
Likely benefit, low risk of adverse events 
Quality of evidence Low, abstract of pooled data from 3 RCTs 
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6. In patients with active PsA-related dactylitis what is the impact of IL17 inhibitors on 
symptoms and adverse events? 
IL17 inhibitors can be considered as second line therapy in the treatment of refractory of 
moderate to severe dactylitis  




desirable and undesirable 
effects 
Demonstrated benefit (secukinumab), potential risk of 
serious adverse events 
Quality of evidence Low, abstract data only from RCT 






1. In patients with active psoriasis what is the impact of topical therapies on symptoms and 
adverse events? 
Topical therapies are recommended as the basic approach to treat any psoriasis.  It is 
recommended as the sole therapy for mild disease, and combined with systemic 
therapies can be used in more active disease.  The combination of calcipotriol and 
betamethasone is considered the gold standard for plaque psoriasis.  Exceptions on 
specific anatomical sites (eg face, genitals) apply. 




desirable and undesirable 
effects 
Minimal undesirable effects (mild irritation of the skin), 
short term desirable effects (good clinical efficacy) 
Quality of evidence High quality  





2. In patients with active psoriasis what is the impact of conventional disease modifying 
anti-rheumatic drugs (cDMARDs) on symptoms and adverse events? 
Conventional DMARDs (methotrexate, leflunomide, cyclosporin) are recommended as a 
first line therapy for psoriasis  
Strength of recommendation – strongly recommended 
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Factor Comment 
Balance between 
desirable and undesirable 
effects 
Clear desirable effect. Favorable balance between 
desirable and undesirable effects in psoriasis in the 
presence or absence of PsA 
Quality of evidence Moderate quality 





3. In patients with active psoriasis what is the impact of TNF inhibitors on symptoms and 
adverse events? 
TNF inhibitors should be used to treat psoriasis in people who are DMARD naïve or 
DMARD failures 




desirable and undesirable 
effects 
Clear desirable effect. Favorable balance between 
desirable and undesirable effects in psoriasis in the 
presence or absence of PsA 
Quality of evidence High Quality RCT data for adalimumab, certolizumab, 
etanercept, golimumab, infliximab 
Values and preferences well established  values and preferences 
Costs (resource 
allocation) 
High cost.  
 
4. In patients with active psoriasis what is the impact of IL12/23 inhibitor on symptoms and 
adverse events? 
IL12/23 inhibitors should be used to treat psoriasis in people who are DMARD naïve or 
DMARD failures 




desirable and undesirable 
effects 
Clear desirable effect. Favorable balance between 
desirable and undesirable effects in psoriasis in the 
presence or absence of PsA 
Quality of evidence High Quality RCT data  





5. In patients with active psoriasis what is the impact of IL17 inhibitors on symptoms, 
disease progression and adverse events?  
IL17 inhibitors (brodalumab, ixekizumab, secukinumab) should be used to treat psoriasis 
in people who are DMARD naïve or DMARD failures. 
Strength of recommendation – strongly recommended 
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Factor Comment 
Balance between 
desirable and undesirable 
effects 
Clear desirable effect. Favorable balance between 
desirable and undesirable effects in psoriasis in the 
presence or absence of PsA 
Quality of evidence High Quality RCT data  





6. In patients with active psoriasis what is the impact of apremilast on symptoms and 
adverse events?  
Apremilast should be used to treat psoriasis in people who are DMARD naïve or 
DMARD failures 




desirable and undesirable 
effects 
Clear desirable effect. Minimal serious side effects. 
Favorable balance between desirable and undesirable 
effects in psoriasis in the presence or absence of PsA 
Quality of evidence High Quality RCT data  






7. In patients with active psoriasis about to start systemic therapy for PsA, should 
concomitant topicals be used? 
Concomitant topical therapy can usually be limited to emollients and pharmacotherapy of 
single lesions or sites in limited psoriasis as many systemic treatments for PsA will have 
a beneficial effect on the skin. 




desirable and undesirable 
effects 
Minimal undesirable effects (mild irritation of the skin), 
short term desirable effects (good clinical efficacy) 
Quality of evidence Moderate quality  





8. In patients with markedly active psoriasis about to start systemic therapy for PsA, should 
certain therapies be used in preference? 
In patients with markedly active psoriasis, the following therapies for PsA should be used 
in preference: methotrexate, cyclosporin, TNFi, IL12/23i, IL17i, apremilast 
Strength of recommendation – strongly recommended 
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Factor Comment 
Balance between 
desirable and undesirable 
effects 
The above-mentioned drugs all exhibit a good safety 
profile combined with sufficient to excellent efficacy whe 
used to treat PsA and/or PsO    
Quality of evidence High quality RCTs 
Values and preferences Acceptable to patients, oral drugs may be preferred 
Costs (resource 
allocation) 
Low costs (cDMARDs) 
High costs (TNFi, IL12/23i, IL17i, apremilast) 
 
Nail psoriasis 
1. In patients with nail psoriasis what is the impact of topical therapies (calcipotriol, 
tacrolimus, and tazarotene) on symptoms and adverse events? 
Topical therapies (calcipotriol, tacrolimus, and tazarotene) can be considered for 
symptom improvement in nail psoriasis  




desirable and undesirable 
effects 
Likely mild improvement in disease, serious adverse 
effects are unlikely 
Quality of evidence Lower quality clinical trials 





2. In patients with nail psoriasis what is the impact of procedural therapies (including 
pulsed dye laser and intralesional corticosteroids) on symptoms and adverse events? 
Procedural therapies (including pulsed dye laser and intralesional corticosteroids) can be 
considered for symptom improvement in nail psoriasis  




desirable and undesirable 
effects 
Likely mild improvement in disease, serious adverse 
effects are unlikely 
Quality of evidence Lower quality clinical trials 





3. In patients with active nail psoriasis what is the impact of conventional disease modifying 
anti-rheumatic drugs (cDMARDs) on symptoms and adverse events? 
cDMARDs (cyclosporine, leflunomide, acitretin and methotrexate) can be considered for 
the treatment of nail psoriasis  
Strength of recommendation – conditionally recommended 
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Factor Comment 
Balance between 
desirable and undesirable 
effects 
Likely mild-to-moderate improvement in disease, serious 
adverse effects are more likely than topical or 
procedural options. 
Quality of evidence Lower quality clinical in most, except higher quality 
RCTs evaluating methotrexate 





4. In patients with active active nail psoriasis what is the impact of TNF inhibitors on 
symptoms and adverse events? 
TNF alpha inhibitors are recommended as initial or second line therapy in the treatment 
of refractory moderate to severe active nail psoriasis 




desirable and undesirable 
effects 
Likely significant improvement in disease, potential risk 
for serious adverse effects 
Quality of evidence High quality 





5. In patients with active active nail psoriasis what is the impact of IL12/23 inhibitors on 
symptoms and adverse events? 
Ustekinumab is recommended as a second line therapy in the treatment of refractory of 
moderate to severe active nail psoriasis  




desirable and undesirable 
effects 
Likely significant improvement in disease, potential risk 
for serious adverse effects 
Quality of evidence High quality 





6. In patients with active active nail psoriasis what is the impact of IL17 inhibitors on 
symptoms and adverse events? 
IL17 inhibitors can be considered as a second line therapy in the treatment of refractory 
of moderate to severe active nail psoriasis  
Strength of recommendation – conditionally recommended 
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Factor Comment 
Balance between 
desirable and undesirable 
effects 
Likely moderate improvement in disease, potential risk 
for serious adverse effects 
Quality of evidence Single lower quality clinical trial 
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GRAPPA Treatment Recommendations: 
PICO Questions for Comorbidities/Extraarticular Manifestations 
 
The following recommendations should be addressed by the patient’s treating clinicians 
including the rheumatologist, dermatologist, primary care physician, and/or other members of 
the care team.  The implementation of these recommendations may vary according to local 
and/or national guidelines. 
 
PICO 1: In patients with PsA, should cardiovascular risk factors be addressed? 
 
Summary: There is a substantive body of work suggesting an increased risk of cardiovascular 
disease among patients with psoriatic arthritis (PsA).  However, there are no studies that 
address mitigation of cardiovascular risk and long-term outcomes as a result of cardiovascular 
risk. 
 
Recommendation: Given evidence suggesting that PsA is associated with increased 
cardiovascular risk, a cardiovascular risk assessment should be strongly considered for all 
patients with PsA.  
 
Grade strength of recommendation: Strong 
 
Factor  Comment  
Balance between desirable 
and undesirable effects  
Low risk of undesirable effects, particularly given that this 
recommendation is also a recommendation for the general 
population 
Quality of evidence  No studies 
Values and preferences  Not clear  
Costs (resource allocation)  Generally low cost but not clear  
 
PICO 2: In patients with PsA, should screening for diabetes be performed? 
 
Summary: A number of studies have now suggested an increased prevalence and incidence of 
diabetes among patients with PsA.  However, there are no studies addressing long term 
outcomes in patents with PsA as a result of screening for diabetes.  However, this is now a 
recommendation for the general population over age 45. 
 
Recommendation: Given the association of diabetes with PsA, fasting glucose or hemoglobin 
A1C should be considered in all patients with PsA. 
 
Grade strength of recommendation: Weak 
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Factor  Comment  
Balance between desirable 
and undesirable effects  
Low risk of undesirable effects  
Quality of evidence  No studies 
Values and preferences  Not clear  
Costs (resource allocation)  Generally low cost but not clear  
 
PICO 3: In patients with PsA, should obesity and acheivement/maintenance of a healthy 
body weight be addressed? 
 
Summary: Several studies have suggested that body mass index (BMI) may influence not only 
the development of psoriasis and PsA but also may impact disease activity and response to 
therapy.  Lower body weight and weight loss have been associated with beneficial therapeutic 
effects for both TNF alpha inhibitors in patients with PsA or psoriasis alone and for cyclosporine 
in patients with psoriasis.  Among patients with PsA, a recent prospective study found that 
obesity was associated with a Hazard Ratio of 4.9 (CI 3.02-7.87) for not achieving minimal 
disease activity (MDA).  Of those that achieved MDA at 12 months, obesity was a significant risk 
factor for relapse at 24 months.  Additionally, two recent studies suggesting improvement in 
response to therapy (achieving MDA) in patients with lower body weight. 
 
Recommendation: Patients should be encouraged to achieve and maintain a healthy body 
weight. 
 
Grade strength of recommendation: Strong 
 
Factor  Comment  
Balance between desirable 
and undesirable effects  
Low risk of undesirable effects 
Quality of evidence  Good evidence from two RCT for improved efficacy of TNF 
alpha inhibitors with lower body weight. 
Values and preferences  Not clear  
Costs (resource allocation)  Generally low cost but not clear  
 
PICO 4: Among patients with PsA, how should the risk for eye disease or gastrointestinal 
side effects be addressed? 
 
Summary: Among patients with PsA, there is an association with uveitis and other ophthalmic 
disorders including keratitis, blepharitis, conjunctivitis, episcleritis, and scleritis.  Additionally, 
there is an increased risk for Crohn’s disease among patients with PsA.  There are no studies 
addressing interventions to address these risks. 
 
Recommendation: Because PsA can be associated with ophthalmic disease and inflammatory 
bowel disease, rheumatologists should ask about relevant symptoms and should consider 
referral. 
 
Grade strength of recommendation: Strong 
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Factor  Comment  
Balance between desirable 
and undesirable effects  
Low risk of undesirable effects 
Quality of evidence  No studies 
Values and preferences  Not clear  
Costs (resource allocation)  low cost  
 
PICO 5: Among patients with PsA utilizing TNF alpha inhibitors, should monitoring for 
skin cancer be performed? 
 
Summary: Among patients with PsA, non-melanoma skin cancer is the most common form of 
cancer.  Given that many patients with PsA have had extended courses of ultraviolet light 
therapy, these patients may be at increased risk for skin cancer.  There are no studies 
addressing long term benefits of skin cancer screening in patients with PsA on 
immunosuppressive therapies. 
 
Recommendation: Consider periodically performing skin examinations for the detection of skin 
cancer in patients with PsA utilizing TNF alpha inhibitors.  
 
Grade strength of recommendation: Strong 
  
Factor  Comment  
Balance between desirable 
and undesirable effects  
Low risk of undesirable effects 
Quality of evidence  No studies 
Values and preferences  Not clear  
Costs (resource allocation)  Generally low cost but may add an additional dermatologist 
visit  
 
PICO 6: In patients with PsA beginning an immunosuppressive therapy, should 
screening for hepatitis C (HCV) and hepatitis B (HBV) be performed? 
 
Summary:  Infection with HBV or HCV has implications for therapy selection in PsA.  For 
example, methotrexate may cause increased liver toxicity in patients with HCV or HBV, and 
TNF alpha inhibitors have been associated with reactivation of HBV.  Additionally, both HCV 
and HBV have been associated with inflammatory arthritis (although there is not strong 
evidence for an association with PsA in particular).  Thus, knowledge of HBV or HCV status 
prior to initiating therapy is beneficial.  There are no studies addressing long term benefits of 
screening for HBV or HCV in patients with PsA. 
 
Recommendation: Strongly consider screening for HCV and HBV prior to beginning therapy with 
immunosuppressive agents.   
 
Grade strength of recommendation: Strong 
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Factor  Comment  
Balance between desirable 
and undesirable effects  
Low risk of undesirable effects 
Quality of evidence  No studies 
Values and preferences  Not clear  
Costs (resource allocation)  Cost of blood tests may vary by country  
 
PICO 7: Among patients with PsA, should screening for human immunodeficiency virus 
(HIV) be performed prior to initiating an immunosuppressive therapy? 
 
Summary: Given that HIV is an immunosuppressed state, adding an immunosuppressive 
therapy requires special monitoring.  Thus, knowledge of the presence of HIV infection is 
important.  There are no studies addressing long term benefits of HIV screening in patients with 
PsA. 
 
Recommendation: Screening for HIV should be considered in patients with risk factors prior to 
starting immunosuppressive agents. 
 
Grade strength of recommendation: Strong 
  
Factor  Comment  
Balance between desirable 
and undesirable effects  
Low risk of undesirable effects 
Quality of evidence  No studies 
Values and preferences  Not clear  
Costs (resource allocation)  Cost of HIV testing may vary by country 
 
PICO 8: Among patients with PsA, should tuberculosis (TB) screening be performed 
before initiating a biologic therapy? 
 
Summary:  Therapies such as the TNF alpha inhibitors increase the risk for symptomatic TB 
among patients with latent TB.  Thus, screening for latent TB and staring therapy when detected 
prior to initiating a biologic therapy is advisable.  There are no studies addressing long term 
benefits of TB screening in patients with PsA. 
 
Recommendation: Patients should be screened for latent TB infection prior to starting a biologic 
agent.   
 
Grade strength of recommendation: Strong 
  
Factor  Comment  
Balance between desirable 
and undesirable effects  
Low risk of undesirable effects 
Quality of evidence  No studies 
Values and preferences  Not clear  
Costs (resource allocation)  Low cost but cost of screening may vary by country 
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PICO 9: Among patients with PsA, should screening for depression be performed? 
 
Summary: Depression is common among patients with PsA and one new therapy (apremilast) 
has been associated with depression. 
 
Recommendation: Consider screening for depression in all patients with PsA. 
 
Grade strength of recommendation: Strong 
  
Factor  Comment  
Balance between desirable 
and undesirable effects  
Low risk of undesirable effects 
Quality of evidence  No studies 
Values and preferences  Not clear  
Costs (resource allocation)   
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ABSTRACT (n = 232) 
Objective:  Update the 2009 Group for Research and Assessment of Psoriasis and 
Psoriatic Arthritis (GRAPPA) treatment recommendations for the spectrum of 
manifestations affecting patients with psoriatic arthritis (PsA).   
Methods:  GRAPPA rheumatologists, dermatologists, and PsA patients drafted 
overarching principles for the management of PsA patients based on consensus at 
face-to-face meetings and via online surveys.  We published literature reviews 
regarding treatment for the key domains of PsA (arthritis, spondylitis, enthesitis, 
dactylitis, skin, and nail disease), and convened a new group to identify pertinent 
comorbidities and their effect on treatment.  Finally, we drafted treatment 
recommendations for each of the clinical manifestations and assessed the level of 
agreement for the overarching principles and treatment recommendations among 
GRAPPA members, with an online questionnaire.  
Results:  Six overarching principles had at least 80% agreement among both health 
care professionals (HCPs; n=135) and patient research partners (PRPs; n=10).  We 
developed treatment recommendations and a schema incorporating these principles for 
arthritis, spondylitis, enthesitis, dactylitis, skin, and nail disease, and comorbidities in the 
setting of PsA, using the GRADE process.  Over 80% agreement was reached for 
approval of the individual recommendations and the overall schema. 
Conclusion:  Herein, we present overarching principles and updated treatment 
recommendations for the key manifestations of PsA, including related comorbidities, 
based on a literature review and consensus of GRAPPA members (rheumatologists, 
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dermatologists, other HCPs, and PRPs).  Further updates are anticipated as the 
therapeutic landscape in PsA evolves. 
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 Psoriatic arthritis (PsA), a disease characterized by inflammatory arthritis, 
enthesitis, dactylitis, and spondylitis in patients with psoriasis,(1, 2) is remarkably 
diverse in presentation and course.  To assist the clinician in the management of PsA, 
the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), 
a global association of over 500 rheumatologists, dermatologists, and patient research 
partners (PRPs) previously published treatment recommendations in 2009(3) based on 
a systematic evidence review published in 2006.(4-11)  To be clinically relevant, such 
recommendations must be dynamic, requiring re-evaluation and appropriate 
modification over time.  In PsA, significant recent developments in pathophysiology and 
disease assessment, particularly the important contribution of comorbidities coupled 
with major therapeutic advances, necessitated an update of the GRAPPA 
recommendations. 
 GRAPPA investigators and PRPs formed groups focused on the clinical domains 
of PsA:  peripheral arthritis, axial disease, enthesitis, dactylitis, skin, and nail disease, 
with a new group focused on comorbidities.  In addition, a representative from each 
group also focused on treatment safety.  Each group then conducted a systematic 
literature review of the PsA treatment literature,(12) and excerpted and published the 
evidence base for treatment effect for each of the domains.(13-19)  We applied the 
GRADE approach to formulate these recommendations,(20) which included 
determination of the strength of recommendation of each therapy (strong, conditional), 
based on the quality and breadth of evidence that the treatment can achieve desirable 
effects (e.g., reduction of morbidity and mortality, improvement in quality of life, 
reduction in burden of treatment and resource utilization), contextualized to individual 
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patient and social considerations.(20)  We created a series of PICO questions (vide 
infrasee supplementary online data) to address crucial practical questions faced by 
clinicians when making specific treatment choices.  The final treatment schema was 
critically reviewed and edited via in-person discussion and online survey.  It is important 
to note that the purpose of these recommendations is to provide optimal care for PsA 
patients regardless of economic or political considerations. 
 
OBJECTIVE 
 We developed these GRAPPA recommendations to provide up-to-date 
systematic and evidence-based guidance for the treatment and management of adult 
patients with PsA.  These recommendations are not specifically relevant for patients 
with juvenile idiopathic arthritis or psoriasis only.  As noted, updated recommendations 
were required due to significant advances in the field since the 2009 GRAPPA 
treatment recommendations.  For example, several new compounds were approved 
since the 2006 literature review and further evidence has accumulated on existing 
therapies.  The target audience for these GRAPPA recommendations is anyone 
involved in the treatment of PsA patients.   
 
METHODS 
 To help frame these updated GRAPPA recommendations, we developed new 
overarching principles for the treatment of PsA.  Initially drafted by a small working 
group, these overarching principles were refined through several rounds of 
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dissemination to members, followed by live review and discussion at GRAPPA 
meetings.  Subsequently, we posted the principles online for further comment and to 
obtain agreement among GRAPPA membership. GRAPPA members updated the 
reviews that were previously published,(13-19) reviewing subsequent literature within 
six sub-groups addressing peripheral arthritis, axial disease, enthesitis, dactylitis, 
psoriasis, and nail disease in the setting of PsA.  A central literature search was 
performed in collaboration with University of Leeds Library as detailed previously(12) in 
2013 with relevant papers given to the groups.  We convened an additional group to 
assess relevant comorbidities and they performed an new independent literature review. 
The psoriasis and nail group were led by dermatologists and rheumatologists led the 
musculoskeletal manifestation groups. The review of the evidence to create treatment 
recommendations was performed using the GRADE system.(20)  As the basis for the 
recommendations, each group developed appropriate PICO (population, intervention, 
comparator, outcomes) questions,(20) and then gathered relevant evidence to support 
the recommendation for individual drugs, classes of drugs, and treatment approaches 
within the six disease domains of PsA as well as the comorbidities group.  
Recommendations per the GRADE system could be for or against a treatment, and 
could be strong or conditional, based upon the best scientific evidence and relevant 
clinical context per the GRADE system.  Evidence was combined from the central 2013 
literature review and additional literature reviews performed within the groups. To 
ensure that the recommendations were not outdated rapidly, each group completed a 
further literature update and review of abstracts through the American College of 
Rheumatology (ACR) Annual Meeting in November 2014, and the American Academy 
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of Dermatology meeting in March 2015.  The comorbidities group performed a individual 
literature searches for each comorbidity that was identified as a key issue in PsA at 
earlier GRAPPA meetings(19, 21). 
The entire group decided that recommendations based on high quality studies 
published only as abstracts should be considered conditional only and clearly 
demarcated by lighter text in the treatment schema.  The group acknowledged that 
these abstracts would likely be published as peer reviewed manuscripts in the near 
future and that the data would impact treatment decisions.  The recommendations for 
specific agents within each domain were summarized in a treatment table and reviewed 
via an online survey by the GRAPPA membership (with the supporting PICO questions) 
to allow feedback, followed by a vote to assess lev l of agreement.   
 Using these evidence-based data, each group summarized their treatment 
recommendations in a flowchart to guide therapy.  Input from each group was combined 
into a single schema, which was assessed bysent to the full GRAPPA membership 
(including the group/committee members) via Survey Monkeyan online survey for 
feedback and agreement. 
Throughout the development of these recommendations, GRAPPA members 
who are pharmaceutical industry representatives have been excluded from participation 
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 Six overarching principles for the care of patients with PsA were finalized after 
extensive feedback.  Agreement was ≥80% among GRAPPA members (135 health care 
providers and 10 patient research partners) for all of these principles from both 
physicians and PRPs (Table 1).  The majority of disagreements related to minor 
wording changes, which were incorporated where possible following this survey, 
although a repeat survey was not performed. 
 
GRADE Recommendations for Therapies 
 Each group produced a number of PICO questions addressing the efficacy and 
safety of the different therapies, developing a GRADE based strong/conditional 
recommendation for each therapy within their domain (Supplementary Material 1).  
These are summarized in Table 2 showing which therapies are strongly or conditionally 
recommended within the domains.  A survey of GRAPPA members showed an 87.2% 
support (n=176) for this summary table, including 83.3% of PRPs (n=6). 
 
GRADE Recommendations for Comorbidities  
 The comorbidities group also produced a number of PICO questions addressing 
recommendations for the investigation and management of relevant comorbidities 
(Supplementary Material 2).  Evidence for these issues is limited and the majority of 
these recommendations rely on expert opinion. 
 Identifying comorbidities is critical in the optimal management and treatment of 
PsA patients.  Common comorbidities include cardiovascular disease (CVD), diabetes, 
Page 80 of 112
John Wiley & Sons
Arthritis & Rheumatology
For Peer Review
05 July 2015 Page 12 of 44 
obesity, metabolic syndrome, osteoporosis, non-alcoholic fatty liver disease (NAFLD), 
and depression; in addition, some comorbidities might be considered extra-articular 
manifestations of disease, such as inflammatory bowel disease (IBD) and ophthalmic 
disease (e.g., uveitis).  Given the increased prevalence and incidence of CVD and 
diabetes among PsA patients, appropriate screening is recommended.  All PsA patients 
should be encouraged to achieve and maintain a healthy body weight.  This is of 
specific relevance to PsA, as patients with normal body weight using tumor necrosis 
factor inhibitors (TNFi) appear to have a higher likelihood of reducing their disease 
activity than do overweight PsA patients.(22-24)  Given the association of ophthalmic 
disease with the spondyloarthritidies and an increased risk for IBD among PsA patients, 
consideration of screening for eye disease and gastrointestinal disease is 
recommended as a part of the review of systems.  Screening should also be considered 
for anxiety or depression and for skin cancer in patients with both a history of ultraviolet 
(UV) phototherapy and TNFi use.  Comorbidities such as NAFLD, osteoporosis, and 
malignancy also may influence management but have been less commonly associated 
with PsA. 
 Recommendations for treatment of comorbidities in PsA are summarized in 
Table 3. Screening for Human Immunodeficiency Virus, Hepatitis B Virus, Hepatitis C 
Virus, and tuberculosis should be strongly considered, in accordance with local 
guidelines and standards of medical practice, before initiation of therapies that may 
potentially alter normal immune responses.  Depression and anxiety have a high 
prevalence in PsA patients; of note, a warning to weigh the risks and benefits of 
treatment among patients with a history of depression and/or suicidal thoughts/behavior 
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has been added to the package insert materials in the USA for new drugs for PsA and 
psoriasis.  Although screening and management of comorbidities may be no different 
than for the general population, it is nevertheless important to actively identify them in 
order to optimize the care of patients with PsA.   
 
Treatment Schema 
 Each disease domain group designed a flowchart for treatment of their domain 
using the GRADE recommendations for therapies previously developed.  These were 
combined into a single schema for the management of PsA.  Following feedback from 
the membership, the distinction between mild, moderate and severe disease, which was 
included in the previous GRAPPA grid, was removed because the cut-offs are not 
evidence-based or applicable to all patients.  Figure 1 outlines potential therapeutic 
routes described as standard or expedited to allow therapy to be tailored to the 
individual patient.  Individual treatment decisions with each patient may be dependent 
on disease activity, prognostic factors, comorbidities, and local access to therapies.  
Central to the schema is the concept that optimal care is an iterative process.  As 
alluded to in the overarching principles, we strongly recommend repeated evaluation 
over time and alteration in therapy as appropriate. The schema was circulated to the full 
GRAPPA membership and 87.9% approved (n=176), including all six PRPs.  For clarity, 
it was decided to use the historical term “DMARD” for conventional systemic drugs such 
as methotrexate and sulfasalazine, as this is commonly used nomenclature.  It should 
be noted that this term is not meant to imply that such therapies have “disease 
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modifying” impact on radiographic damage in PsA.  “Biologics” was used to describe the 
group of biological therapies targeting TNF, IL12/23, IL17 and others. 
 This schema is designed to assist in decision making for individual patients, with 
assessment of which disease domains are involved and their relevant comorbidities.  
Many patients have multiple manifestations of their disease and the choice of treatment 
should be considered carefully to ensure that it addresses as many of those as 
possible.  Within this consideration, it is likely that selection of therapy will be driven by 
the most severe element of a person’s disease.  The possibilities for how the schema 
and supporting materials might actually be used are illustrated through case examples 
in Table 4.  
 Further notes regarding this schema are provided below. 
 Peripheral arthritis:  Nonsteroidal anti-inflammatory drugs (NSAIDs) are 
conditionally recommended for use in peripheral arthritis to improve symptoms of the 
disease with caution due to their potential adverse effects.  Corticosteroids are 
conditionally recommended for peripheral arthritis either given systemically or intra-
articularly with the smallest doses required (usually less than 7.5 mg/day) and for short  
requiredperiods  to minimize adverse effects including psoriasis flare, after CS 
withdrawal.  In disease-modifying antirheumatic drug (DMARD)-naïve patients, both 
DMARDs (methotrexate, leflunomide, sulfasalazine; cyclosporine is not recommended 
due to small evidence of its efficacy and its toxicity profile) and TNFi are strongly 
recommended for treatment.  In many instances, DMARDs may be used first, but 
consideration should be given to early escalation of therapy particularly in patients with 
poor prognostic factors (e.g., raised inflammatory markers, high active joint counts).  
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Despite the lack of evidence from randomized controlled trials (RCTs), DMARDs are 
recommended based on data from observational studies, their low costs and universal 
access, and the lack of evidence that a short time delay in the introduction of more 
effective therapies would impact long-term function and quality of life.  Data concerning 
the PDE4i apremilast in DMARD-naïve patients are only currently available in abstract 
form, hence this is conditionally recommended.  For patients failing DMARDs, PDE4i or 
biologics (including TNFi, interleukin [IL]12/23 inhibitor) are strongly recommended; at 
present a conditional recommendation is given for IL17i as the phase III data are only 
available in abstract form.  It must be noted that there are no data available assessing 
the impact of PDE4i on radiographic damage in contrast to the TNFi, IL12/23i and IL17i.  
One phase 2 RCT showed modest effects with abatacept on joint symptoms in PsA 
Mease(25). Phase 3 trials are being conducted but results are not as yet known, but 
asSince the manufacturer has not submitted it for regulatory approval anywhere in the 
world, it was not included in the current recommendations. We recognize that off-label 
use may occur based on the positive phase 2 study.  There is no definitive evidence to 
date assessing the benefit of concomitant DMARDs with biologic therapies.  In the TNFi 
RCTs, similar efficacy results were commonly seen with or without methotrexate.  
However, registry data suggest a longer persistence of effect of the monoclonal 
antibodies with concomitant DMARDs, particularly with infliximab.  In the case of 
biologic failure either due to adverse events or inefficacy, a large volume of 
observational data are now available supporting the conditional recommendation of 
“switching” to an alternative biologic either within a drug class or to a drug with a 
different mode of action.  Many more recent RCTs include patients who have previously 
Page 84 of 112
John Wiley & Sons
Arthritis & Rheumatology
For Peer Review
05 July 2015 Page 16 of 44 
failed one or more biologic therapy(26-28).  There is limited data available on combining 
therapies and treatment strategy in PsA as outlined in the peripheral arthritis evidence 
review (13). MTX in combination with biologic agents, either non-TNFi or anti-TNFi, may 
have a role, but most studies suggest that the combination does not improve clinical 
symptoms beyond those attained by biologic monotherapy (13). Some registry studies 
have shown improved survival, mainly for infliximab (13). 
 Axial disease:  The treatment recommendations for axial disease are derived 
from diagnostic criteria, screening, monitoring and response to therapy in ankylosing 
spondylitis (AS) since these data are not available for axial PsA.  For patients with axial 
symptoms who have not responded to NSAIDs, physiotherapy, and sacroiliac injections 
(when appropriate), initiation of TNFi is recommended; DMARDs are not effective for 
treatment of this domain.  No evidence is available for efficacy of sulfasalazine in axial 
disease within AS or PsA.(29)  Clinical trial data showing efficacy for secukinumab 
(phase III trial)(30) and ustekinumab (an open-label proof-of-concept trial with 20 
patients)(31) have been published in AS, but these agents are currently not approved 
for AS or axial PsA.  Formal published data on switching agents for axial disease are 
not available. 
 Enthesitis:  NSAIDs are the first line agents in treatment of enthesitis based on 
expert opinion, however data from RCTs are lacking (32).  Physiotherapy is also often 
prescribed although formal studies of efficacy are lacking.  In one study with defined 
enthesitis endpoints and placebo controls, sulfasalazine was not effective (33), and no 
published data support efficacy of other DMARDs in placebo-controlled studies (15, 32). 
There is high quality evidence for the effectiveness ofso the next step is the biologics, 
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TNFi andor ustekinumab (15).  Data on the efficacy of PDE4i (34) and secukinumab 
(35) for enthesitis in PsA are published as abstracts only.  Formal data on switching are 
not available.  
 Dactylitis:  In contrast to enthesitis, DMARDs were recommended as a first step 
in dactylitis based on limited studies for this indication.  Corticosteroid injections should 
also be considered, although no formal studies of this intervention have been published.  
There are efficacy data for biologics (TNFi or ustekinumab), but data on switching are 
not available.  Published abstracts show efficacy for both PDE4i(34) and 
secukinumab(35) for dactylitis, but again, data on switching agents are not available.  
 Skin disease: Topical agents are generally the first level of treatment for 
psoriasis, particularly milder disease, followed by phototherapy and DMARDs. 
Treatment may be initiated with topical therapies in combination with phototherapy or 
DMARDs in patients with wide-spread disease.  For patients who do not respond to 
these therapies, biologics are recommended.  Biologics may be first-line therapy, with or 
without topical therapies and DMARDs, in certain patients.  Switching from one DMARD 
to another, from a DMARD to a biologic, or from one biologic to another can be done.  
 Nail disease:  Recommendations for the treatment of nail disease in PsA rely on 
data from studies in skin psoriasis; there are relatively few studies, some of which had 
methodologic issues affecting their interpretation.(11, 18)  The best data were produced 
in studies of biologics, particularly the TNF inhibitors, and these agents would certainly 
be recommended for PsA patients with moderate to severe nail involvement.  High 
quality data are also published on alternative biologics, including ustekinumab and IL-17 
inhibitors, and these agents could be considered alternative biologic therapies to TNFi.  
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Efficacy on nail disease in psoriasis RCTs has been confirmed for PDE4i in multiple 
abstracts but no published paper was available at this time.  Despite the paucity of data, 
topical agents, corticosteroid injections, or non-biologic DMARDs could be considered, 
especially for patients with milder involvement or contraindications to other therapies.  
  
Research Agenda 
 Tremendous advances have transpired in the therapeutic approach to PsA.  
Indeed, such progress, along with a desire to codify the data into recommendations that 
could assist clinicians caring for PsA patients, were a major impetus to the formation of 
GRAPPA.  Substantial developments since the initial GRAPPA recommendations 
necessitated their update.  With greater success, the goals of treatment have become 
increasingly elevated, as reflected in the overarching principles presented herein.  In 
order to better achieve those lofty goals, we eagerly anticipate research into and data 
from a number of key areas.  
 1.  Outcome measures.  It is hoped that development, refinement, and 
ultimately, implementation of PsA-specific outcome measurements will facilitate 
evaluation and treatment of individual patients in the clinic as well as further enhancing 
PsA research.  
 2.  Biomarkers.  Despite tremendous advances in therapies and treatment 
strategies, there is still an unmet need identifying the optimal therapeutic approach for 
individual PsA patients.  Also, the heterogeneity of PsA remains largely unexplained.  
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Although we know that 30% of psoriasis patients will develop PsA, often after several 
years, we cannot reliably identify such patients.  
 3.  Better Identification and treatment of patients.  Several reports emphasize 
potentially poor outcome for patients with PsA.(36, 37)  Moreover, recent evidence 
demonstrated that a delay in diagnosis and delayed access to appropriate treatment are 
key predictors of poor outcome, in terms of response to therapy,(38) joint damage,(39) 
and functional ability.(39, 40)   Unfortunately, data from market surveys and other 
sources show that many PsA patients may not be receiving appropriate therapy.  For 
example, in a telephone survey of more than 700 PsA patients, the majority were on 
topical therapy only (31%) or no treatment at all (28%), and 16% reported not seeing 
any healthcare provider in the past year for their PsA.(41)  
 4.  Treatment strategies.  Novel treatment strategies are being assessed in 
PsA.  For example, treat-to-target, a concept well established in rheumatoid 
arthritis,(42) is now being explored in PsA.  Understanding the overall long-term utility of 
this approach in PsA will be crucial to defining the best treatment approach.  Another 
concept that has been more extensively studied in RA is whether therapies can be 
tapered or even discontinued by patients reaching their therapeutic goals.  It remains to 
be determined whether this will be possible, and for which patients, in PsA.  
 
DISCUSSION 
 Herein, the members of GRAPPA present updated evidence-based treatment 
recommendations for patients with PsA.  Optimal management of PsA using a 
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multidisciplinary and multispecialty approach is required but remains a major challenge.  
The heterogeneity of the disease requires assessment of multiple PsA domains to 
identify appropriate treatments for each individual.  Assessment of comorbidities is also 
key when planning therapy and can either lead to an escalation in therapy for related 
diseases, such as inflammatory bowel disease or uveitis, or requires a dose alteration 
or restriction of therapies in the presence of liver disease or increased risk of infection. 
 These recommendations are evidence-based wherever possible and result from 
literature searches updated to October 2014 and also include data from the American 
Academy of Dermatology Annual Meeting in March 2015.  We performed our evidence 
review using GRADE, the format recommended by a number of international bodies 
including the World Health Organization.  The recommendations had strong patient 
involvement (PRPs were represented in each group) and their feedback was 
incorporated in the overall schema and tables presented here.  First, international 
experts and patients reached consensus in the individual groups over multiple 
iterations, both for the individual domains and for the overall project.  Subsequently, we 
obtained consensus on the formal recommendations from the entire GRAPPA 
membership and PRPs and we recorded the extent of agreement for recommendations 
in each domain, including comorbidities.  To maximise impartiality, GRAPPA members 
from the pharmaceutical industry were excluded from discussions and voting on the 
recommendations.  To maximise feedback, all non-pharmaceutical members were 
invited to respond although their individual conflicts of interest are not available. 
 While other relevant information may be available, it is worth noting that these 
recommendations were not developed specifically for patients with psoriasis alone, nor 
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for children with PsA.  They are designed to be relevant across international boundaries 
although it must be recognized that access to some therapies is not universal.  We also 
recognize that limited available evidence exists particularly for some relevant clinical 
questions.  For example, high quality evidence to support the standard treatment 
approaches in PsA are not published in every domain, and we lack evidence-based 
studies on the potential additive or even synergistic benefit of combinations of agents 
(e.g., methotrexate and TNFi).  Most importantly, evidence is not available at this time to 
support optimal treatment pathways, such as the treatment of early PsA, the overall 
utility of treat-to-target in PsA, and whether it is better to switch to treatments with a 
different mechanism of action in patients who have insufficient clinical responses to one 
agent in a class.  
 The members of GRAPPA agreed to include the latest recent literature including 
high quality abstracts from recent meetings; thus, agents not yet licensed or approved 
for PsA were included.  These agents are clearly demarcated in the schema using grey 
font and details of these therapies are provided in the text.  In these cases, drugs are 
only given conditional recommendations, but have been included to provide up-to-date 
information. 
 These recommendations represent the literature at present but the 
recommendations may change with new evidence in future.  Just as these 
recommendations are updates of those published in 2009, they will require further 
updating to ensure that the recommendations reflect current evidence and practice.
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1 The ultimate goals of therapy for all patients with 
psoriatic arthritis (PsA) are: a) To achieve the lowest 
possible level of disease activity in all domains of 
disease; as definitions of remission and low or minimal 
disease activity become accepted, these will be 
included in the goal.  b) To optimize functional status, 
improve quality of life and wellbeing, and prevent 
structural damage to the greatest extent possible. c) To 
avoid or minimize complications, both from untreated 
active disease and from therapy. 
92.6% 80% 
2 Assessment of patients with PsA requires consideration 
of all major disease domains, including peripheral 
arthritis, axial disease, enthesitis, dactylitis, psoriasis, 
and nail disease.  The impact of disease on pain, 
function, quality of life, and structural damage should be 
examined.  In addition, activity in other potential related 
83.7% 80% 
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conditions should be considered, including 
cardiovascular disease, uveitis, and inflammatory bowel 
disease.  Multidisciplinary and multispecialty 
assessment and management will be most beneficial for 
individual patients. 
3 Clinical assessment ideally includes patient-reported 
measures with a comprehensive history and physical 
examination, often supplemented by laboratory tests 
and imaging techniques (e.g., x-ray, ultrasound, MRI).  
The most widely accepted metrics that have been 
validated for PsA should be utilized whenever possible. 
88.9% 80% 
4 A comprehensive assessment of relevant comorbidities 
(including but not restricted to obesity, metabolic 
syndrome, gout, diabetes, cardiovascular disease, liver 
disease, depression and anxiety) should be undertaken 
and documented.   
85.2% 100% 
5 Therapeutic decisions need to be individualized, and 
are made jointly by the patient and their doctor.  
89.6% 80% 
Page 98 of 112
John Wiley & Sons
Arthritis & Rheumatology
For Peer Review








Treatment should reflect patient preferences, with the 
patients provided with the best information and relevant 
options provided to them.  Treatment choices may be 
affected by various factors, including disease activity, 
structural damage, comorbid conditions and previous 
therapies. 
6 Ideally, patients should be reviewed promptly, offered 
regular evaluation by appropriate specialists, and have 
treatment adjusted as needed in order to achieve the 
goals of therapy. Early diagnosis and treatment is likely 
to be of benefit. 
89.6% 80% 
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Italicized text identifies conditional recommendations for drugs without current regulatory 
approvals or where recommendations are based on abstract data only.   
Italicized text in brackets identifies a conditional recommendation based only on abstract data 
from a small open-label proof-of-concept trial.  
ADM = adalimumab, AS = ankylosing spondylitis, CD20i = CD20 inhibitor, CS = corticosteroids, 
CyA = cyclosporin, CZP = certolizumab, DMARDs = disease modifying anti-rheumatic drugs, 
GOL = golimumab, IA = intra-articular, IL6i = interleukin 6 inhibitor, IL17i = interleukin 17 inhibitor, 
IL12/23i = interleukin 12/23 inhibitor, INF = infliximab, LEF = leflunomide, MTX  = methotrexate, 
NSAIDs = nonsteroidal anti-inflammatory drugs, PDE4i = phosphodiesterase 4 inhibitor 
(apremilast), SEC = secukinumab, SIJ = sacroiliac injections, SSZ = sulfasalazine, TNFi = tumor 
necrosis factor inhibitor  
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C ? NI NI NI NI NI NI NI NI NI NI ? NI 
Congestive Heart 
Failure 
C C NI NI NI NI NI ? ? ? ? ? ? NI 
Obesity NI NI NI NI C NI NI NI NI NI NI NI NI NI 
Metabolic Syndrome NI C NI NI C NI NI NI NI NI NI NI NI NI 
Diabetes NI C NI NI C NI NI NI NI NI NI NI NI NI 
Ulcerative Colitis ? NI NI A NI NI OL NI A A NI A NI NI 
Crohn’s Disease ? NI NI A OL NI NI NI A A A NI NI NI 
Uveitis NI P# NI NI NI NI NI ? P P NI NI NI NI 
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Osteoporosis NI C NI NI NI NI NI NI NI NI NI NI NI NI 
Malignancy NI NI NI NI NI NI NI C C C C C ? NI 
Fatty Liver Disease C NI NI C C C NI NI NI NI NI NI NI NI 
Chronic Kidney 
Disease 
C NI NI NI C ? SM NI NI NI NI NI NI NI 
Depression NI NI NI NI NI NI NI NI NI NI NI NI NI ? 
Chronic Hepatitis B * C NI NI NI C C NI SM SM SM SM SM ? NI 




       SM SM SM SM SM ?  
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A    = Approved for primary therapy of the comorbid condition 
C    = Reason for caution 
NI = no information available 
OL  =  Off-label use for the therapy of the comorbid condition 
P    =  Preferred therapy 
SM =  Requires special monitoring 
?    =  Data insufficient but concerns have been raised 
*  When treating patients with chronic infections that can affect the liver, consider consultation with 
providers having expertise in the area. 
# Corticosteroids used as preferred therapy for uveitis are given as topical and/or intraocular injections in 
preference to oral steroids 
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Table 4:  Case studies using treatment recommendations 
Case 
1 
43-year-old man, psoriasis for 10 years, psoriatic arthritis for 1 year.  Current 
evaluation: SJ2 TJ3 (PIPs and DIPs); no axial symptoms; 3 tender enthesial 
sites; no dactylitis; psoriasis self-rated 1/10 with BSA 2% (elbows, knees, 
buttocks) and no nail involvement.  Prior therapy has been only NSAIDs, and 
topical steroids, which he remains on at present.  Additional history notable for 
3 episodes of iritis over the past 18 months, treated with steroid eye drops.  
 
Treatment recommendation options: TNF inhibitor, DMARDMTX 
 
Discussion:  With reference to the treatment schema, for the individual domains 
of peripheral arthritis and enthesitis and skin, csDMARD treatment, e.g.LEF, 
MTX, could be a viable choice given the relatively modest activity in each 
domain.  However, the presence of recurrent iritis (see comorbidity table) along 
with the combination of individual domains, supports escalation of therapy.  
Hence, TNF inhibitor therapy is a reasonable choice, and should be discussed 
with the patient.  In some areas, clinicians may be obliged to use MTX before 
access to a TNF inhibitor is allowed.  Other newer therapies could be 
considered (e.g., IL-12/23 inhibitor, PDE4i [apremilast], IL-17 inhibitors) 
although clinicians have longer experience with older medications.  
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59-year-old woman, psoriasis for 15 years, psoriatic arthritis for 9 months.  
Current evaluation: SJ6, TJ8 (knees, wrist, fingers); no axial symptoms; 
1 tender enthesial site; no dactylitis; psoriasis self-rated 4/10 with BSA 8% 
(trunk, scalp, arms, legs) and nail involvement.  Prior treatment: cyclosporine 
led to hypertension, NSAIDs worsened renal function.  Cannot access UV 
therapy.  Currently on topical steroids.  Additional history notable for poorly 
controlled diabetes, obesity, and recurrent sinusitis with one hospitalization for 
pneumonia in the past year.   
 
Treatment recommendation options: methotrexate, PDE4i, leflunomide, 
biologics 
 
Discussion:  Referring to the treatment schema, moderate to severe activity in 
the peripheral joints and skin seem to be the main drivers of therapy.  However, 
comorbidities (see table) are very important in this case.  Excluding failed 
therapies, these options remain.  MTX is a difficult choice due to obesity and 
diabetes as potential drivers of hepatotoxicity with MTX.  The recurrent 
infections are a concern across most immunomodulatory therapies.  Clearly, 
extended discussion of potential risk/benefit with the patient is required, along 
with close monitoring.  Assessment of existing radiographic damage may also 
inform treatment choice. 
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34 year old woman with psoriasis for 4 years, psoriatic arthritis for 2 years.  
Current evaluation: SJ8 TJ12 (wrist, knee, fingers, toes); no axial symptoms; 
7 tender enthesial sites (knees, feet, pelvic rim); dactylitis of 2 toes (causing 
inability to walk as required for her work); skin self-rated 1/10 with 1% BSA 
(trunk) without nail involvement.  Prior treatments: methotrexate tried, but 
caused liver function abnormalities possibly related to alcohol use.  Current 
treatment with NSAIDs, topical low dose steroids, and assist devices (heel cup 
for foot enthesitis).  Treatment with TNF was recommended but the patient was 
hesitant to do injections or infusions.  After considerations of options, and 
discussion of sulfasalazine, leflunomid , and PDE4i, patient chose sulfasalzine.  
On re-evaluation 4 months later, there was no improvement.  Patient agreed to 
therapy with TNF inhibitor.  After 3 months of therapy, she reported 
improvement across domains of “around 40%” (but was not achieving the 
minimal disease activity criteria) and also noted mild but bothersome injection 
site reactions.  
 
Treatment recommendations (in no order of preference): A different TNF 
inhibitor, IL-12/23 inhibitor, IL-17 inhibitor, leflunomide, and PDE4i. 
 
Discussion:  Referring to the treatment schema, there are several alternatives 
as noted.  Given the significant impact on the patient’s quality of life, treatment 
needs to be highly effective for this patient.  In this case, it can be debated 
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whether the patient is a “TNFi failure,” and also whether switching to alternative 
TNFi or to another biologic with a different mode of action would be preferred.  
BSA = body surface area; DIP = distal interphalangeal joint; DMARD = disease 
modifying anti-rheumatic drug; MTX = methotrexate, NSAID = nonsteroidal anti-
inflammatory drug; PDE4i = phosphodiesterase 4 inhibitor (apremilast); PIP = proximal 
interphalangeal joint; SJ = swollen joint; TJ = tender joint; TNFi = tumor necrosis factor 
inhibitor 
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Figure Legend 
 
Figure 1:  GRAPPA Treatment Schema for Active PsA 
Grey text identifies conditional recommendations for drugs without current regulatory 
approvals or where recommendations are based on abstract data only. 
 
DMARDs = disease modifying anti-rheumatic drugs, IL17i = interleukin 17 inhibitors, 
IL12/23i = interleukin 12/23 inhibitors, LEF = leflunomide, MTX = methotrexate, NSAIDs 
= nonsteroidal anti-inflammatory drugs, PDE4i = phosphodiesterase 4 inhibitor 
(apremilast), SSZ = sulfasalazine, TNFi = tumor necrosis factor inhibitor 
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